Display options
Share it on

Oncol Lett. 2017 Mar;13(3):1518-1524. doi: 10.3892/ol.2017.5658. Epub 2017 Jan 27.

Anti-apoptotic protein Lifeguard does not act as a tumor marker in breast cancer.

Oncology letters

Viktor Maurer, Kerstin Reimers, Hans J Lück, Peter M Vogt, Vesna Bucan

Affiliations

  1. Department of Plastic, Hand and Reconstructive Surgery, Hanover Medical School, D-30652 Hanover, Germany.
  2. Gynecologic Oncology Practice, D-30177 Hanover, Germany.

PMID: 28454284 PMCID: PMC5403417 DOI: 10.3892/ol.2017.5658

Abstract

The aim of the present study was to use an enzyme-linked immunosorbent assay (ELISA) to determine the concentrations of Lifeguard (LFG) protein in the serum of 36 patients diagnosed with breast cancer and to compare these values with the concentrations of LFG protein in the serum of 7 healthy volunteers in order to detect a possible association between the expression of LFG in the serum and the degree of malignancy of the disease. Although there is no direct association between the LFG protein concentration in the serum and the degree of malignancy of breast cancer, a statistically significant distribution of the concentration in all investigated samples was observed. This indicated an association between the LFG protein concentration in human serum with a currently unknown factor.

Keywords: Lifeguard; breast cancer; tumor marker

References

  1. J Biochem. 2009 Dec;146(6):821-32 - PubMed
  2. Oncol Lett. 2011 May;2(3):419-422 - PubMed
  3. Ann Oncol. 2014 Aug;25(8):1650-6 - PubMed
  4. Apoptosis. 2010 Jul;15(7):814-21 - PubMed
  5. Curr Biol. 2000 Jan 27;10(2):R84-7 - PubMed
  6. Genes Cells. 2012 Jul;17(7):559-67 - PubMed
  7. Oncol Rep. 2014 Oct;32(4):1335-40 - PubMed

Publication Types